Swerdlow SH, Campo E, Harris NL (2017) WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. IARC, Lyon, p.291–7

Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW et al (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:1676–1679

Article  CAS  PubMed  Google Scholar 

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

Article  CAS  PubMed  Google Scholar 

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857–1861

Article  CAS  PubMed  Google Scholar 

Scott DW, Gascoyne RD (2014) The tumor microenvironment in B cell lymphomas. Nat Rev Cancer 14:517–534

Article  CAS  PubMed  Google Scholar 

de Jong D, Enblad G (2008) Inflammatory cells and immune microenvironment in malignant lymphoma. J Intern Med 264:528–536

Article  PubMed  Google Scholar 

Muris JJF, Meijer CJLM, Cillessen S a. GM, Vos W, Kummer JA, Bladergroen BA, et al (2004) Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 18:589–96.

Kridel R, Steidl C, Gascoyne RD (2015) Tumor-associated macrophages in diffuse large B-cell lymphoma. Haematologica 100:143–145

Article  PubMed  PubMed Central  Google Scholar 

Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S (2008) Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma. Haematologica 93:193–200

Article  CAS  PubMed  Google Scholar 

Zou W (2006) Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 6:295–307

Article  CAS  PubMed  Google Scholar 

Wang J, Ke X-Y (2011) The four types of Tregs in malignant lymphomas. J Hematol Oncol 4:50–50

Article  PubMed  PubMed Central  Google Scholar 

Riihijärvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O et al (2015) Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica 100:238–245

Article  PubMed  PubMed Central  Google Scholar 

Hasselblom S, Hansson U, Sigurdardottir M, Nilsson-Ehle H, Ridell B, Andersson P-O (2008) Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathol Int 58:529–532

Article  PubMed  Google Scholar 

Meyer PN, Fu K, Greiner T, Smith L, Delabie J, Gascoyne R et al (2011) The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol 135:54–61

Article  PubMed  Google Scholar 

Olweny CL (1990) Cotswolds modification of the Ann Arbor staging system for Hodgkin’s disease. J Clin Oncol 8:1598–1598

CAS  PubMed  Google Scholar 

Cheson BD (2015) Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol 4:5

PubMed  Google Scholar 

El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D et al (2015) Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: a Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol 90:1041–1046

Article  CAS  PubMed  Google Scholar 

Chang K-C, Huang G-C, Jones D, Lin Y-H (2007) Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 13:6666–6672

Article  CAS  PubMed  Google Scholar 

Linderoth J, Edén P, Ehinger M, Valcich J, Jerkeman M, Bendahl P-O et al (2008) Genes associated with the tumor microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma. Br J Haematol 141:423–432

Article  CAS  PubMed  Google Scholar 

Lippman S, Spier C, Miller T, Slymen D, Rybski J, Grogan T (1990) Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. Mod Pathol 3:361–367

CAS  PubMed  Google Scholar 

Hasselblom S, Sigurdadottir M, Hansson U, Nilsson-Ehle H, Ridell B, Andersson P-O (2007) The number of tumor-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol 137:364–373

Article  CAS  PubMed  Google Scholar 

Nam SJ, Go H, Paik JH, Kim TM, Heo DS, Kim CW et al (2014) An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk Lymphoma 55:2466–2476

Article  CAS  PubMed  Google Scholar 

Wada N, Zaki MAA, Hori Y, Hashimoto K, Tsukaguchi M, Tatsumi Y et al (2012) Tumor-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 60:313–319

Article  PubMed  Google Scholar 

Li Y-L, Shi Z-H, Wang X, Gu K-S, Zhai Z-M (2019) Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count. BMC Cancer 19:1049

Article  PubMed  PubMed Central  Google Scholar 

Lee N-R, Song E-K, Jang KY, Choi HN, Moon WS, Kwon K et al (2008) Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 49:247–256

Article  CAS  PubMed  Google Scholar 

Serag El-Dien MM, Abdou AG, Asaad NY, Abd El-Wahed MM, Kora MAE-HM. (2017) Intratumoral FOXP3+ regulatory T cells in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol 25:534–42